Shares of Axsome Therapeutics (AXSM -5.22%) were up by 7.5% as of 11:55 a.m. EDT Monday. The gain came after the company announced a delay in the Food and Drug Administration's review of its application for AXS-05 to be approved as a treatment for major depressive disorder.
The FDA had originally set a Prescription Drug User Fee Act (PDUFA) date of Aug. 22 to complete its review of the regulatory filing for AXS-05. However, Axsome said that the agency informed it on Aug. 20 that it wouldn't meet that target date.
Ordinarily, this kind of announcement would cause a drugmaker's shares to fall. However, Axsome had already told investors in its second-quarter update earlier this month that the FDA had "identified deficiencies" in its regulatory filing. The company warned then that there could be a delay in the approval process.
Investors were likely pleased with Monday's news because Axsome said that the FDA had not requested any additional information; the agency is continuing to review the company's application.
There's one big question for Axsome now: When will the FDA make its decision on AXS-05? Unfortunately, the agency didn't provide a new date. Axsome is also waiting on the FDA to announce its decision on acceptance of its filing for AXS-07 in treating migraine.